Another pioneer study from MD Anderson Cancer Center reported a FNR of 5% and an accuracy of 98% of MIB in patients with TN-type and HER2-positive tumours with or without hormone-positive types and found a breast pCR of 47.5% in their feasibility trial [22]. Here, ERBB2 is linked to neoplasm.